Naproxene Eg (Naproxen)

Naproxen blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are responsible for producing prostaglandins. By lowering prostaglandin levels, it diminishes the inflammatory response, reduces pain signalling, and helps bring down elevated body temperature.

The appropriate dose of Naproxene Eg is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Naproxen is generally avoided during the third trimester of pregnancy because of potential fetal cardiovascular effects. Use during early pregnancy or while breastfeeding should only be considered if the prescriber judges that the benefit outweighs the risk. Consultation with a healthcare provider is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both naproxen and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Naproxen has a longer half‑life, often allowing twice‑daily dosing, whereas ibuprofen typically requires three‑four times daily dosing. Individual response, safety profile and physician preference guide the choice between them.

Naproxene Eg should be stored at temperatures below 25 °C in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Naproxene Eg is taken orally, usually with a full glass of water. It can be taken with food or milk to lessen gastrointestinal discomfort, but the tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe renal impairment, and rare but life‑threatening skin reactions. Patients should be alert for signs of abdominal pain, black stools, chest discomfort, sudden swelling, or rash and seek medical attention promptly.

Naproxene Eg should be avoided in individuals with known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment. It is also contraindicated in the third trimester of pregnancy.